Consortium led by Prophylix Pharma AS has been granted up to €6 million by EU for the development of a prophylactic treatment of severe bleeding and death in newborns caused by Fetal/Neonatal Alloimmune Trombocytopenia (FNAIT).

Further information about the project and the consortium can be found at the PROFNAIT project web site (www.profnait.eu).